|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Besides, FDG PET-CT identified sacroiliitis in one patient and adenocarcinoma in one patient.
|
29564671 |
2018 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The multivariate logistic model identified FDG-PET "AD" SPM classification (Expβ = 19.35, 95% C.I.
|
29387532 |
2018 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, <sup>18</sup>F-FDG PET and clinical assessments were collected in a cohort of 422 individuals [including 130 with AD, 130 with MCI, and 162 healthy controls (HCs)] from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and 44 individuals (including 22 with AD, and 22 HCs) from Huashan Hospital, Shanghai, China.
|
30956687 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review aims to help readers understand the role of <sup>18</sup>F-FDG PET/CT imaging in the investigation of cognitive impairment and how the advent of amyloid PET/CT imaging may hold the key to radically changing management of the most common form of dementia - Alzheimer's disease.
|
30982329 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included 38 patients with mild-to-moderate AD (mean age 67 ± 7 years, mean MMSE score 24 ± 4, mean years of education 14 ± 4; 20 men, 18 women) in whom a [<sup>18</sup>F]AV-1451 scan (a measure of tau pathology) and an [<sup>18</sup>F]FDG scan (a measure of neuronal function) were available.
|
31183635 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Experiments on Alzheimer's Disease Neuroimaging Initiative database show that the proposed method outperforms most FDG-PET-based classification algorithms, especially for classifying progressive MCI (pMCI) from stable MCI (sMCI).
|
30028716 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In 81 Veterans diagnosed with dementia due to AD, we conducted a cluster-based correlation analysis to assess the relationships between recency and recognition memory scores from the CERAD Word Learning Task and cortical metabolic activity measured using [<sup>18</sup>F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET).
|
27876444 |
2017 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The use of graph theory for the quantification of [<sup>18</sup>F]FDG brain PET covariance, including the definition of an entropy metric, proved to be particularly relevant for Alzheimer's disease, showing an association with the progression of the pathology.
|
30792460 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively compared <sup>18</sup>F-FDG PET-CT imaging patterns from seven iNPH patients (mean age 74 ± 6 years) to age and sex matched controls, as well as patients diagnosed with clinical Alzheimer's disease dementia (AD), Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD), and behavioral variant frontotemporal dementia (bvFTD).
|
29876274 |
2018 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To update the evidence and reassess the accuracy of 18F-FDG-PET for detecting people with MCI at baseline who would clinically convert to Alzheimer's disease (AD) dementia at follow-up.
|
30010119 |
2018 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using florbetapir PET and cerebrospinal fluid (CSF) measures to define amyloid-β (Aβ) positivity, 40 Aβ negative (Aβ-) cognitively unimpaired controls (CU; 76 ± 5y), 76 Aβ positive (Aβ+) persons with MCI (76 ± 7y) and 51 Aβ + persons with probable AD dementia (75 ± 7y) from the AD Neuroimaging Initiative (ADNI) were included in this study with baseline and 2-year follow-up FDG PET scans.
|
30101060 |
2018 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with MCI, <sup>18</sup>F-FDG PET exclusively demonstrated quantitative hypometabolism and a component in the precuneus, indicating higher sensitivity to detect preclinical AD compared with the currently used pulsed ASL MRI sequence.
|
29762090 |
2018 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<sup>68</sup>Ga-DOTATATE PET imaging was compared to [<sup>18</sup>F]FDG PET imaging in 42 patients with atherosclerosis.
|
28385306 |
2017 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<sup>68</sup>Ga-DOTATATE PET imaging was compared to [<sup>18</sup>F]FDG PET imaging in 42 patients with atherosclerosis.
|
28385306 |
2017 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer.
|
29135102 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study suggests that the four selected SNPs are not robust determinants of breast cancer risk, but that the two SNPs in SMUG1 might modestly alter the risk of breast cancer.
|
21427733 |
2011 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To help interpret measurements in breast tissue and breast tumors from <sup>18</sup>F-FDG PET scans, we studied the influence of age in measurements of PET parameters in normal breast tissue and in a breast cancer (BC) population.
|
30112113 |
2018 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Utility of <sup>18</sup> F-FDG PET/CT in pre-surgical risk stratification of patients with breast cancer.
|
31587025 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Biodistribution analysis and positron emission tomography (PET) imaging of [<sup>68</sup>Ga]DOTA-VAP were carried out in subcutaneous MDA-MB-231 and MCF-7 human breast cancer tumor models with [<sup>18</sup>F]FDG PET imaging as comparison.
|
31452065 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET/CT can monitor metabolic activity in early breast cancer during neoadjuvant systemic therapy (NST), but it is unknown if the metabolic breast and axillary response differ.
|
28545563 |
2017 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sixteen patients starting endocrine treatment for de novo or progressive breast cancer bone metastases were prospectively recruited to undergo [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT scans before and 8 weeks after treatment.
|
30250989 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A 67-year-old woman with prolonged fever, thrombocytopenia, and renal dysfunction underwent FDG PET/CT to evaluate underlying causes, including malignancy.
|
30222681 |
2018 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Lymph node tuberculosis mimicking malignancy on <sup>18</sup>F-FDG PET/CT in two patients: A case report.
|
28587415 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The 122 recipients underwent a total of 133 FDG PET/CT scans performed for a suspected malignancy (66 %) or an infection (34 %).
|
27838763 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Incidental thyroid uptake is found in approximately 2.5% of patients who undergo FDG PET for nonthyroid malignancy; approximately a third of the FDG PET thyroid incidentalomas are malignant, including primary thyroid malignancies and metastasis.
|
31135518 |
2019 |